• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 5:07:14 PM ET
    $CDAK
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CDAK alert in real time by email
    SC 13G 1 d53537dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    Codiak BioSciences, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    192010 10 6

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     

    CUSIP No. 192010 10 6   Page 2 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Flagship Ventures Fund V, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

         5     

      SOLE VOTING POWER

     

       0

         6   

      SHARED VOTING POWER

     

      1,143,177

         7   

      SOLE DISPOSITIVE POWER

     

       0

         8   

      SHARED DISPOSITIVE POWER

     

      1,143,177

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,143,177

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      6.1%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN


     

    CUSIP No. 192010 10 6   Page 3 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Flagship V VenturesLabs Rx Fund, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

         5     

      SOLE VOTING POWER

     

       0

         6   

      SHARED VOTING POWER

     

      978,177

         7   

      SOLE DISPOSITIVE POWER

     

       0

         8   

      SHARED DISPOSITIVE POWER

     

      978,177

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      978,177

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      5.2%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN


     

    CUSIP No. 192010 10 6   Page 4 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Flagship Ventures Fund V General Partner LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

         5     

      SOLE VOTING POWER

     

       0

         6   

      SHARED VOTING POWER

     

      2,121,354

         7   

      SOLE DISPOSITIVE POWER

     

       0

         8   

      SHARED DISPOSITIVE POWER

     

      2,121,354

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,121,354

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      11.3%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO


     

    CUSIP No. 192010 10 6   Page 5 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Flagship VenturesLabs V LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

         5     

      SOLE VOTING POWER

     

      0

         6   

      SHARED VOTING POWER

     

      485,949

         7   

      SOLE DISPOSITIVE POWER

     

       0

         8   

      SHARED DISPOSITIVE POWER

     

      485,949

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      485,949

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      2.6%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO


     

    CUSIP No. 192010 10 6   Page 6 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Flagship VentureLabs V Manager LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

         5     

      SOLE VOTING POWER

     

      0

         6   

      SHARED VOTING POWER

     

      485,949

         7   

      SOLE DISPOSITIVE POWER

     

      0

         8   

      SHARED DISPOSITIVE POWER

     

      485,949

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      485,949

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      2.6%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO


     

    CUSIP No. 192010 10 6   Page 7 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Flagship Pioneering, Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

         5     

      SOLE VOTING POWER

     

      0

         6   

      SHARED VOTING POWER

     

      485,949

         7   

      SOLE DISPOSITIVE POWER

     

      0

         8   

      SHARED DISPOSITIVE POWER

     

      485,949

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      485,949

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      2.6%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO


     

    CUSIP No. 192010 10 6   Page 8 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Noubar B. Afeyan, Ph.D.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

         5     

      SOLE VOTING POWER

     

      0

         6   

      SHARED VOTING POWER

     

      2,607,303

         7   

      SOLE DISPOSITIVE POWER

     

      0

         8   

      SHARED DISPOSITIVE POWER

     

      2,607,303

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,607,303

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      13.9%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN


    CUSIP No. 192010 10 6   Page 9 of 14 Pages

     

    Item 1(a).

    Name of Issuer:

    Codiak BioSciences, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    35 CambridgePark Drive, Suite 500

    Cambridge, MA 02140

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Flagship Ventures Fund V, L.P. (“Flagship Fund V”)

    Flagship V VentureLabs Rx Fund, L.P. (“Flagship Fund V Rx”)

    Flagship Ventures Fund V General Partner LLC (“Flagship V GP”)

    Flagship VentureLabs V LLC (“VentureLabs V”)

    Flagship VentureLabs V Manager LLC (“VentureLabs V Manager”)

    Flagship Pioneering, Inc. (“Flagship Pioneering”)

    Noubar B. Afeyan, Ph.D. (“Dr. Afeyan”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    c/o Flagship Pioneering Inc.

    55 Cambridge Parkway, Suite 800E

    Cambridge, Massachusetts 02142

     

    Item 2(c).

    Citizenship:

     

    Flagship Fund V

       Delaware

    Flagship Fund V Rx

       Delaware

    Flagship V GP

       Delaware

    VentureLabs V

       Delaware

    VentureLabs V Manager

       Delaware

    Flagship Pioneering

       Delaware

    Dr. Afeyan

       United States of America

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.0001 par value per share (“Common Stock”).

     

    Item 2(e).

    CUSIP Number:

    192010 10 6

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    CUSIP No. 192010 10 6   Page 10 of 14 Pages

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 18,767,674 shares of outstanding Common Stock, as reported in the Issuer’s report on Form 10-Q filed with the Securities and Exchange Commission on November 19, 2020.

    Flagship V GP is the general partner of each of Flagship Fund V and Flagship Fund V Rx, and, as such, may be deemed to beneficially own the shares beneficially owned by Flagship Fund V and Flagship Fund V Rx.

    Dr. Afeyan is the manager of Flagship V GP and, as such, may be deemed to beneficially own shares beneficially owned by Flagship V GP.

    VentureLabs V Manager is the manager of VentureLabs V and, as such, may be deemed to beneficially own the shares beneficially owned by VentureLabs V.

    Flagship Pioneering is the manager of VentureLabs V and, as such, may be deemed to beneficially own the shares beneficially owned by VentureLabs V Manager.

    Dr. Afeyan is the Chief Executive Officer, sole stockholder and director of Flagship Pioneering and, as such, may be deemed to beneficially own shares beneficially owned by Flagship Pioneering.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.

    Material Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13G.


    CUSIP No. 192010 10 6   Page 11 of 14 Pages

    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 16, 2021

     

    FLAGSHIP VENTURES FUND V, L.P.

    By:

      Flagship Ventures Fund V General Partner LLC
    General Partner
     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    Manager

     

    FLAGSHIP V VENTURELABS RX FUND, L.P.

    By:

      Flagship Ventures Fund V General Partner LLC General Partner
     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    Manager

     

    FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC
     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    Manager

     

    FLAGSHIP VENTURELABS V LLC

    By:

      Flagship VentureLabs V Manager LLC,
    Manager
     

    By: Flagship Pioneering, Inc.,

    Manager

     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    CEO, Sole Stockholder & Director


    CUSIP No. 192010 10 6   Page 12 of 14 Pages

     

    FLAGSHIP VENTURELABS V MANAGER LLC

    By:

      Flagship Pioneering, Inc.
    Manager
     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    CEO, Sole Stockholder & Director

     

    FLAGSHIP PIONEERING, INC.

     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    CEO, Sole Stockholder & Director

     

    /s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.


    CUSIP No. 192010 10 6   Page 13 of 14 Pages

    EXHIBIT 1

    AGREEMENT

    The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

    Date: February 16, 2021

     

    FLAGSHIP VENTURES FUND V, L.P.

    By:

      Flagship Ventures Fund V General Partner LLC
    General Partner
     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    Manager

     

    FLAGSHIP V VENTURELABS RX FUND, L.P.

    By:

      Flagship Ventures Fund V General Partner LLC General Partner
     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    Manager

     

    FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC
     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    Manager

     

    FLAGSHIP VENTURELABS V LLC

    By:

      Flagship VentureLabs V Manager LLC,
    Manager
     

    By: Flagship Pioneering, Inc.,

    Manager

     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    CEO, Sole Stockholder & Director


    CUSIP No. 192010 10 6   Page 14 of 14 Pages

     

    FLAGSHIP VENTURELABS V MANAGER LLC

    By:

      Flagship Pioneering, Inc.
    Manager
     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    CEO, Sole Stockholder & Director

     

    FLAGSHIP PIONEERING, INC.

     

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

       

    Noubar B. Afeyan, Ph.D.

       

    CEO, Sole Stockholder & Director

     

    /s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.

    Get the next $CDAK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDAK

    DatePrice TargetRatingAnalyst
    2/22/2022$34.00 → $24.00Outperform
    Wedbush
    2/11/2022$19.00Buy
    Goldman Sachs
    More analyst ratings

    $CDAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process

      CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The Company expects

      3/27/23 7:00:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference

      CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference. Codiak's Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:00 am ET and the Company will also be hosting one-on-one meetings at the conference. A live webcast of the fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. A

      11/28/22 1:00:00 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

      – exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for treatment with exoASO-STAT6 – – Systemically administered exoASO-C/EBPβ demonstrated extra-hepatic delivery and potent systemic anti-tumor activity across multiple myeloid-derived suppressor cell (MDSC) rich tumor models – – A Phase 1 clinical trial of exoASO-STAT6 in patients with advanced hepatocellular carcinoma (HCC), is ongoing; initial data expected in the first half of 2023 – CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a

      11/10/22 9:00:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush reiterated coverage on Codiak BioSciences with a new price target

      Wedbush reiterated coverage of Codiak BioSciences with a rating of Outperform and set a new price target of $24.00 from $34.00 previously

      2/22/22 8:48:06 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Goldman Sachs initiated coverage on Codiak BioSciences with a new price target

      Goldman Sachs initiated coverage of Codiak BioSciences with a rating of Buy and set a new price target of $19.00

      2/11/22 6:11:40 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Howze Yalonda

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 6:01:07 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Sathyanarayanan Sriram

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 5:19:21 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Konstantinov Konstantin

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 5:13:35 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Codiak BioSciences Inc.

      25-NSE - Codiak BioSciences, Inc. (0001659352) (Subject)

      5/2/23 1:35:25 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form NT 10-K filed by Codiak BioSciences Inc.

      NT 10-K - Codiak BioSciences, Inc. (0001659352) (Filer)

      3/28/23 7:34:56 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak BioSciences Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Codiak BioSciences, Inc. (0001659352) (Filer)

      3/27/23 9:59:55 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Financials

    Live finance-specific insights

    See more
    • Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™

      – Codiak's engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest allowing for increased therapeutic window – – exoSTING and exoIL-12 demonstrated favorable safety and tolerability profile at repeat doses tested and antitumor activity was observed in both injected and uninjected/distal lesions – – Codiak has identified recommended Phase 2 dose for each program and plans to initiate Phase 2 studies for both candidates in the first quarter of 2023 – – Codiak to host conference call and webcast today at 8:00 am ET – CAMBRIDGE, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK),

      6/30/22 6:30:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress

      – Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for exoASO™-STAT6, with clinical trial initiation expected 1H 2022 –                   – Initial safety, PK/PD and efficacy data for exoIL-12™ in CTCL patients anticipated late 1H 2022 – – Progressed preclinical pan-beta coronavirus vaccine program – CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today reported fourth quarte

      3/10/22 4:01:00 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts

      – exoSTING resulted in localized STING pathway activation and dose-dependent immune activation – – Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no systemic exposure to STING agonist, and in a subset of patients, tumor shrinkage in injected and distal non-injected lesions – – Data on objective response rate and recommended Phase 2 dose selection for expansion anticipated 1H 2022 – – Codiak to host conference call and webcast today at 8:00 am ET – CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therap

      11/16/21 6:45:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Codiak BioSciences Inc. (Amendment)

      SC 13G/A - Codiak BioSciences, Inc. (0001659352) (Subject)

      2/14/24 2:23:36 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Codiak BioSciences Inc. (Amendment)

      SC 13G/A - Codiak BioSciences, Inc. (0001659352) (Subject)

      4/10/23 9:37:12 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Codiak BioSciences Inc. (Amendment)

      SC 13G/A - Codiak BioSciences, Inc. (0001659352) (Subject)

      2/14/23 1:02:51 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Leadership Updates

    Live Leadership Updates

    See more
    • Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer

      CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the appointment of David Mauro, M.D., Ph.D., a veteran oncology and immunotherapy drug developer, as Chief Medical Officer. Dr. Mauro will provide leadership and expertise for Codiak's pipeline of clinical development programs through early-stage trials to global regulatory submissions and joins the company's Executive Leadership Team reporting to Douglas E. Williams, Ph.D., President and CEO. "We have been fortunate to work with David since late last year

      5/2/22 9:00:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna

      Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities.  Werner most recently served as Wo

      4/11/22 6:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

      CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for

      2/28/22 9:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations